LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Albion Financial Group UT

Albion Financial Group UT lifted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,974 shares of the medical instruments supplier’s stock after buying an additional 212 shares during the period. Albion Financial Group UT’s holdings in LeMaitre Vascular were worth $264,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. SRS Capital Advisors Inc. increased its holdings in shares of LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 524 shares during the period. Personal CFO Solutions LLC increased its holdings in LeMaitre Vascular by 6.4% in the 4th quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after buying an additional 336 shares during the period. KLR Investment Advisors LLC purchased a new position in LeMaitre Vascular during the 4th quarter worth approximately $351,000. Hennion & Walsh Asset Management Inc. lifted its stake in LeMaitre Vascular by 18.6% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,342 shares of the medical instruments supplier’s stock valued at $421,000 after acquiring an additional 993 shares during the period. Finally, Riverwater Partners LLC increased its stake in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after acquiring an additional 198 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 5,025 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,067,300.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO George W. Lemaitre sold 68,906 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now owns 2,133,428 shares of the company’s stock, valued at $161,500,499.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 5,025 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.62, for a total transaction of $379,990.50. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,067,300.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,431 shares of company stock valued at $6,627,520. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Up 0.1 %

LMAT opened at $81.30 on Thursday. The company has a market cap of $1.83 billion, a PE ratio of 53.84, a price-to-earnings-growth ratio of 2.47 and a beta of 0.89. LeMaitre Vascular, Inc. has a twelve month low of $44.27 and a twelve month high of $84.15. The company has a 50-day moving average price of $77.49 and a 200 day moving average price of $67.18.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The business’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.27 earnings per share. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of research reports. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, June 22nd. JMP Securities upped their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research note on Friday, May 3rd. Roth Mkm reiterated a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a research report on Friday, May 31st. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their price objective for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Finally, Barrington Research boosted their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $77.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.